Orexin clinical trials to participate in…
More info: ClinicalTrials.gov
Upcoming trials:
More info: ClinicalTrials.gov
and other studies focused on Orexin 2 receptor agonists: ClinicalTrials.gov
Has anybody gotten hold of and used Orexin A? I tried but failed in ordering lyophilized poweder from the vendors highlighted by RapAdmin (MedChen Express demands a business address and Target Moi requires an internal product code that I cannot access). So that leaves me with Limitless Life nasal spray, shared by Tim, but I´ll first see if I get any response here.
All the better to compete with new robot replacements.
1 Like
No Sleep, and Neuralink… if you can’t beat them, join them 
And then there is a family in Italy that suffers from FFI, or fatal family insomnia. Caused by a genetic mutation, the disorder has such symptoms as paranoia, hallucinations, severe sweating, and rapid weight loss, ultimately leading to delirium and death.
New Yorker writer D.T. Max wrote a book on the subject, 'The Family That Couldn’t Sleep," and fans of Gabriel Garcia Marquez will remember that the inhabitants of Macondo were seized by an “insomnia plague.”
2 Likes
Direct Peptide Replacement: Biotech’s Multi-Billion Dollar Bet on the Master Switch of Wakefulness
The standard of care for narcolepsy has long been a “band-aid” approach, using broad-spectrum stimulants to mask daytime sleepiness without addressing the underlying pathology. This landscape shifted dramatically in early 2026. The biotech sector is now pivoting toward orexin receptor-2 agonists , a new class of small molecules designed to mimic the missing neuropeptides that maintain the human wake-sleep cycle.
Narcolepsy Type 1 (NT1) is primarily an autoimmune-driven deficiency. The immune system destroys a specific cluster of neurons in the hypothalamus responsible for producing orexin (hypocretin). Without this “master switch,” patients suffer from fragmented sleep, sudden muscle collapse (cataplexy), and cognitive “brain fog”.
The clinical results for the front-runner, Takeda’s oveporexton (TAK-861), suggest a paradigm shift. Unlike previous attempts that failed due to liver toxicity, oveporexton has cleared Phase 2 trials with a high safety profile, significantly extending wakefulness and reducing cataplexy episodes. The industry’s confidence is reflected in Eli Lilly’s recent $6.3 billion acquisition of Centessa Pharmaceuticals’ pipeline, signaling that orexin agonists are viewed not just as narcolepsy drugs, but as potentially revolutionary “cognitive enhancers” or “clean stimulants” for a variety of neurological conditions.
Actionable Insights
For the longevity-focused community, the emergence of orexin agonists represents a new frontier in neurological optimization. While currently targeted at NT1 and NT2, the “pleiotropic” nature of orexin signaling—affecting attention, mood, and memory—suggests these compounds may eventually be used off-label for age-related cognitive decline or “brain fog” associated with neurodegeneration.
-
Pipeline Monitoring: Keep a close watch on alixorexton (ALKS 2680) and ORX750. These are moving into Phase 3 and have shown efficacy in both narcolepsy types, suggesting they could be more versatile than earlier candidates.
-
The Sleep-Cognition Link: The data reinforces that “wakefulness” is not merely the absence of sleep but a peptide-regulated state required for cognitive vigilance. Optimizing endogenous orexin through lifestyle—or eventually via these agonists—could be a key strategy for maintaining executive function in aging.
-
Precision Stimulants: Unlike caffeine or amphetamines, which have broad cardiovascular impacts, orexin agonists target a specific hypothalamic pathway. This offers a more “surgical” approach to alertness with a lower risk of systemic jitteriness, though insomnia and urinary urgency remain noted side effects.
Source:
- Paper/Article: First orexin agonists address root cause of narcolepsy
- Institutions: Stanford University (USA), Takeda (Japan), Centessa Pharmaceuticals (UK/USA), Alkermes (Ireland/USA), Nxera Pharma (Japan).
- Journal: Nature Biotechnology.
- Impact Evaluation: The impact score of this journal is 33.1 (JIF 2024), evaluated against a typical high-end range of 0–60+ for top general science; therefore, this is an Elite impact journal.
I cannot take GLP-1’s due to anhedonia. I wonder if a low dose Orexin-A IN, would counteract this. Is there a low/starting dose that people are using?
A plausible mechanism
“The core experiments involved cross-docking the GLP-1R agonist, Danuglipron, with HCRTR2, and the established Orexin antagonist, Suvorexant, with GLP-1R. Both cross-docking pairs showed favourable binding affinities. The stability of both cross-docked complexes was further confirmed via Molecular dynamics simulation, which demonstrated low-deviation dynamics and persistent binding interactions. These results provide strong molecular and structural evidence that the GLP-1R and HCRTR2 signalling axes converge on common molecular hubs, offering an atomic-level mechanism for their functional interdependence and explaining potential polypharmacological effects of existing drugs. This is the first of its kind, comprehensive in silico framework demonstrating molecular convergence between GLP-1R and HCRTR2.”
Wait but isn’t sleep needed for all sorts of reasons? Repair, cognitive consolidation, immune clearance, insulin sensitivity, and many many more? I’d love to know HOW this is supposed to work without causing damage or incurring hidden tradeoffs? Can someone explain even a plausible road to sustainability?
The only plausible roads I can think of are either:
- Short term acting orexin agonists that you take in the morning and clear by late afternoon.
or - Take orexin agonist in the morning and orexin antagonists at night.
or - A treatment to improve orexin signalling in the brain to be more youthful.
Well there must be more to it than that because the folks with the mutation can go a lifetime on just 4 hours of sleep a night. There’s something here that doesn’t add up. Orexin must sit at the top of an untapped iceberg.
I interpreted your comment as asking how us regular folk can utilize exogenous orexin/agonists.
Orexin certainly is interesting. There are groups looking at orexin based treatments for ADHD, fatigue and more.
My only experience with anything that may upregulate it is modafinil and armodafinil, both which negatively impacted sleep. They’re something I’ll keep in my back pocket for extreme high level work.
1 Like
I’m more interested in understanding how it all works. If you catch my drift, your insomnia from the orexin agonist you tried might not be a problem if your body and brain didn’t miss out from anything in that lost sleep. I just don’t understand how such a thing can be even mechanistically plausible.
I think there is more going on in people who are genetically short sleepers. It isn’t as simple as taking more orexin. Modafinil did negatively impact sleep and health. Improving sleep through other means while using modafinil likely would offset most if not all negative effects.
1 Like
What more do you think is going on in genetic short sleepers? I can’t for the life of me figure it out. My sleep is excellent— both rem and deep and overall sleep duration and consolidation. But if anything I feel like I’ve inherited a long sleep mutation and I NEED a ton of sleep. And it’s becoming harder with age to keep full wakefulness and alertness throughout the day (though I suspect a big part of that is my environment being under stimulating to what I’ve been used to). But if I could take a drug that kept me super alert during the day without jitters and even lowered my need for sleep so I can wake up at 5:30 am and not suffer — neither psychologically nor physiologically — that would be amazing.
1 Like
I don’t know what more is going on but I suspect it is more than just more orexin production. Perhaps a more optimal metabolization, or slower aging of different neurons. Scientists really need to figure this one out and create an intervention to make everyone a “short sleeper”.
I believe that optimization of sleep is one of the best ways we can improve longevity.
I wrote about my theory here Sleep 2.0 – Understanding and Upregulating the Rejuvenating Aspects of Good Sleep
1 Like
A new podcast interview with the CEO of Alkermes, with lots of discussion on the news Orexin targeted drugs in clinical testing:
1 Like
Here’s the current landscape of orexin (OX2R) agonists in clinical development, ranked by anticipated availability — soonest first. Note these are the “wake-promoting” orexin-2 receptor agonists for narcolepsy/sleep disorders, which is where essentially the entire orexin-agonist field sits today.
Ranked by anticipated availability
| Drug (company) | Stage / Phase 3 status | Est. Phase 3 completion | Anticipated launch (if successful) |
|---|---|---|---|
| Oveporexton (TAK-861) — Takeda | Phase 3 complete (FirstLight/RadiantLight in NT1, all endpoints met). NDA accepted, FDA Priority Review, PDUFA Q3 2026 | Done (NT1); NT2 Phase 3 ongoing | H2 2026 / late 2026(US, NT1) — clear front-runner |
| Alixorexton (ALKS-2680) — Alkermes | Phase 3 Brilliance studies initiated Q1 2026 (NT1 & NT2); IH program planned | ~2028 | ~2029 |
| Cleminorexton (ORX750) — Centessa (being acquired by Eli Lilly, close expected Q3 2026) | Registrational/Phase 3 program initiated Q1 2026 (NT1, NT2, IH) | ~2028 | ~2029 |
| TAK-360 — Takeda | Phase 1 → early Phase 2; oral, for NT2 & IH; FDA Fast Track | ~2029–2030 | ~2030+ |
| ORX142 — Centessa/Lilly | Phase 1, clinical studies expanding Q1 2026 | ~2029–2030 | ~2030+ |
| ORX489 — Centessa/Lilly | Phase 1 (IND-stage) | later | early 2030s |
| TAK-495 — Takeda | Early/Phase 1 | later | early 2030s |
| BP1.15205 — Harmony Biosciences | Phase 1; PK data expected mid-2026 | later | early 2030s |
Stalled / discontinued (for completeness)
- JZP-441 (DSP-0187) — Jazz/Sumitomo: Phase 1 paused over visual disturbances and cardiovascular effects; not advancing.
- Danavorexton (TAK-925) — Takeda: IV agent, proof-of-concept established but discontinued for narcolepsy.
- TAK-994 — Takeda: oral, discontinued earlier due to hepatotoxicity (superseded by oveporexton).
Key takeaways
Oveporexton is in a class of its own — it’s the only one with completed Phase 3 data and a pending FDA decision, so it should be the first orexin agonist to market, realistically late 2026, initially for narcolepsy type 1.
Alixorexton and cleminorexton (ORX750) are the clear second wave, both having just entered Phase 3 in Q1 2026, putting them on roughly parallel ~2028 readout / ~2029 launch trajectories, with broader label ambitions (NT1, NT2, and idiopathic hypersomnia). Everything else is Phase 1/early stage, so any launch is 2030 or later and far less certain.
One caveat: only the oveporexton date is firm (tied to an actual PDUFA date). All later dates are my estimates built from standard timelines — roughly 2 years of Phase 3 plus ~10–12 months of regulatory review — and will shift with trial enrollment, readouts, and filing strategy.
Sources:
- Takeda — Positive Phase 3 oveporexton results
- Takeda — FDA accepts NDA / Priority Review, PDUFA Q3 2026
- Alkermes — Phase 3 Brilliance studies initiated
- Centessa Q3 2025 update — ORX750 registrational program
- BioSpace — Lilly’s $6.3B Centessa acquisition
- Harmony Biosciences 8-K — BP1.15205 Phase 1 PK mid-2026
- NeurologyLive — Advances in orexin therapies
- Sleep Review — Jazz halts JZP-441 (DSP-0187)
- PMC review — OX2R agonists for narcolepsy type 1
New data released, and looking good:
Takeda shared results from 2 pivotal studies at the SLEEP 2026 Annual Meeting which showed that oveporexton (TAK-861) improved daily functioning, cognition, and sleep-related symptoms associated with narcolepsy type 1 (NT1).1 Psychiatric Times interviewed Elena Koundourakis, PhD, the head of the Orexin Franchise Development & Neuroscience Programs at Takeda, to learn more.
These new data, she said, suggest restoring orexin signaling may improve “the full spectrum” of NT1 symptoms — not just excessive daytime sleepiness and cataplexy but also cognition, functioning, and nighttime sleep.
https://www.psychiatrictimes.com/view/reducing-microsleeps-oveporextons-impact-on-patient-outcomes
2 Likes
Spotlight On: Alkermes’ NT2 data boost case for broad potential of orexins
PUBLISHED : JUNE 19, 2026
Much of the excitement around orexin 2 receptor (OX2R) agonists hinges on their ability to impact diseases not driven directly by an orexin deficiency, meaning this week’s update for Alkermes’ alixorexton is a win for it and perhaps the entire class.
The backstory
A consensus has already crystallised around an expectation that OX2R agents are poised to revolutionise narcolepsy type 1 (NT1), a condition driven by an insufficiency in the neuropeptide orexin.
Several therapies have generated encouraging clinical data supporting this hypothesis. These include Takeda’s oveporexton and alixorexton, along with cleminorexton from Centessa Pharmaceuticals, which is in the process of being bought out by Eli Lilly for $6.3 billion.
Important as the success of the class is in NT1, some of the more eye-popping sales projections for alixorexton and other OX2R agonists are based instead on their ability to succeed in adjacent indications, beginning — but not ending — with narcolepsy type 2 (NT2).
What happened
On Wednesday, Alkermes presented detailed results from the Vibrance-2 sleep study in which once-daily alixorexton was confirmed as hitting the primary endpoints, demonstrating a significant benefit on the maintenance of wakefulness test (MWT) and Epworth Sleepiness Scale (ESS), in 93 patients with NT2 after eight weeks.
Interestingly, and more tantalisingly, the company also unveiled data looking at exploratory measures beyond wakefulness, which suggest that alixorexton achieved a meaningful improvement on patient-reported outcomes focused on cognition and fatigue. The benefits were observed as early as week two and continued throughout the 13-week open-label extension study.
Why this matters
“When Alkermes showed randomised data in NT1 on cognition, etcetera, it was very encouraging, but it wasn’t 100% clear if we could generalise that to larger indications, because NT1 pts have very low baseline orexin levels,” noted Evercore ISI analyst Umer Raffat.
These new functional findings are especially impressive, according to Raffat, because NT2 is a condition where patients have more normal orexin levels, so the fact that they responded to a therapy like alixorexton suggests that agonising OX2R is having a more profound physiological impact.
3 Likes